Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOLT-201 in ATTR-PN or ATTR-CM
NCT06539208Phase 2Recruiting
- Sponsor
- YolTech Therapeutics
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of YOLT-201 in transthyretin amyloidosis (ATTR), sponsored by YolTech Therapeutics. Started May 2024; status: recruiting.
02
Drugs
YOLT-201
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT06539208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06539208.